Personalis (PSNL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
Annual Meeting scheduled for May 12, 2026, with virtual participation and voting options for shareholders.
Three main proposals: election of two Class I directors, ratification of BDO USA, P.C. as auditor, and advisory approval of executive compensation.
Record date for voting is March 17, 2026, with 104,677,900 shares outstanding.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class I directors for terms expiring in 2029.
Ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay); next say-on-pay vote scheduled for 2027.
Shareholder proposals for the 2027 meeting must be submitted by December 3, 2026.
Board of directors and corporate governance
Board consists of seven directors, with a classified structure supporting continuity.
Majority of directors are independent; CEO is not considered independent.
Chair and CEO roles are separated; annual board and committee self-assessments are conducted.
Board committees: Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
Directors are expected to limit service on other boards and participate in ongoing education.
Latest events from Personalis
- Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.PSNL
Proxy filing2 Apr 2026 - Clinical test volume soared nearly 400% in 2025, with 2026 revenue guided to $78–$80 million.PSNL
Q4 202527 Feb 2026 - Ultra-sensitive ctDNA testing detects cancer recurrence and therapy response earlier than current methods.PSNL
Status Update3 Feb 2026 - Q2 revenue up 35% year-over-year, guidance raised, net loss narrowed, but risks remain.PSNL
Q2 20242 Feb 2026 - Q3 revenue up 41% year-over-year, biopharma surges, and cash runway extends to 2027.PSNL
Q3 202416 Jan 2026 - 14M shares from a $50M private placement registered for resale; no proceeds to the company.PSNL
Registration Filing16 Dec 2025 - 3.5M shares registered for resale after $17.7M private placement with Tempus AI, Inc.PSNL
Registration Filing16 Dec 2025 - 2024 revenue up 15% to $84.6M; net loss narrows; partnerships and MRD drive outlook.PSNL
Q4 20241 Dec 2025 - Board recommends voting for director nominees, auditor ratification, and executive pay approval.PSNL
Proxy Filing1 Dec 2025